Our economics are anchored on Sertkaya et al., Key cost drivers of pharmaceutical clinical trials in the United States (Clinical Trials, 2016) - a peer-reviewed industry-standard reference based on thousands of negotiated CRO contracts in Medidata's CROCAS database.

The Phase 2 CRO contract range ($7M–$20M, median ~$13M) is drawn from that paper. Monitoring's share of contract (15–22%) combines Sertkaya's categorization with updated industry benchmarks from Tufts CSDD and Applied Clinical Trials.

Axiom's addressable share of monitoring (60–75%) is our own decomposition of the monitoring workflow, based on CRO contract analysis and interviews with clinical operations leads.

Axiom's efficiency target (25–40% labor reduction on addressable work) is a target. We publish per-pilot measured efficiency as pilots complete.

The numbers are estimates. Your trial will vary. During a pilot, we'll replace these ranges with measured numbers grounded in your portfolio.